Cases of progressive multifocal leukoencephalopathy can occur in patients treated with the B cell depleting anti-CD20 antibody, rituximab, highlighting the importance of B cell surveillance of the central nervous system (CNS). The lymphoid chemokine, CXCL13, is critical for B cell recruitment and functional organization of peripheral lymphoid tissues, and CXCL13 levels are often elevated in the inflamed CNS. To more directly investigate the role of CXCL13 in CNS B cell migration, its role in animal models of infectious and inflammatory demyelinating disease was examined. During acute alphavirus encephalitis where viral clearance depends on the local actions of anti-viral antibodies, CXCL13 levels and B cell numbers increased in brain tissue over time. Surprisingly, however, CXCL13-deficient animals showed normal CNS B cell recruitment, unaltered CNS virus replication and clearance, and intact peripheral anti-viral antibody responses. During experimental autoimmune encephalomyelitis (EAE), CNS levels of CXCL13 increased as symptoms emerged and equivalent numbers of B cells were identified among the CNS infiltrates of CXCL13-deficient mice compared to control animals. However, CXCL13-deficient mice did not sustain pathogenic anti-myelin T cell responses, consistent with their known propensity to develop more self-limited EAE. These data show that CXCL13 is dispensable for CNS B cell recruitment in both models. The disease course is unaffected by CXCL13 in a CNS infection paradigm that depends on a pathogen-specific B cell response, while it is heightened and prolonged by CXCL13 when myelin-specific CD4+ T cells drive CNS pathology. Thus, CXCL13 could be a therapeutic target in certain neuroinflammatory diseases, but not by blocking B cell recruitment to the CNS.
Introduction
Lymphoid chemokines, also known as homeostatic chemokines, are constitutively expressed in lymphoid organs and control the recruitment and compartmentalization of lymphocytes and antigen presenting cells within these specialized structures (Yoshie et al., 1997; Zlotnik et al., 1999) . CCL19 and CCL21 bind to CCR7 and recruit T cells and dendritic cells (DCs) to T cell areas of secondary lymphoid tissues (Yoshie et al., 1997; Muller et al., 2003) . CXCL12 binds to CXCR4 and attracts multiple immune cell types to lymph nodes and spleen, and along with CXCL13, drives the formation of germinal centers (Campbell et al., 2003; Allen et al., 2004) . CXCL13 is made by stromal cells in B cell follicles, and recruits both B cells and follicular helper T cells to these compartments by acting through its cognate receptor, CXCR5 (Forster et al., 1996; Legler et al., 1998; Ansel et al., 2000; Moser et al., 2002; Muller et al., 2003) . The expression of all lymphoid chemokines in both T and B cell areas of lymphoid organs depends on lymphotoxin (LT) a1b2 and tumor necrosis factor (TNF) signaling in stromal cells that are a main source of these chemoattractants (Mackay and Browning, 1998; Ngo et al., 1999; Fu and Chaplin, 1999) .
Beyond their role in the development and maintenance of lymphoid tissues, the lymphoid chemokines have also been implicated in the perpetuation of tissue inflammation. During chronic inflammation of the synovium and salivary gland, ectopic structures resembling the T and B cell follicles of lymphoid organs have been observed (Hjelmstrom, 2001 ). Evidence supporting a role for lymphoid chemokines in this process of ''lymphoid neogenesis" derives in part from studies showing that transgenic expression of CCL21 or CXCL13 in organs such as the pancreas or thyroid gland is sufficient to cause leukocyte recruitment and the formation of lymphoid structures at these sites (Fan et al., 2000; Luther et al., 2000 Luther et al., , 2002 Chen et al., 2002; Martin et al., 2004) . CXCL13 is expressed in gastric mucosa-associated lymphoid structures that develop in response to Helicobacter pylori infection (Mazzucchelli et al., 1999) , and has also been found in B cell aggregates that develop in the inflamed meninges of mice with experimental autoimmune encephalomyelitis (EAE) and humans with progressive multiple sclerosis (MS) (Magliozzi et al., 2004 (Magliozzi et al., , 2007 Serafini et al., 2004; Aloisi et al., 0889-1591/$ -see front matter Ó 2010 Elsevier Inc. All rights reserved. doi:10.1016/j.bbi.2010.10.002
